resistance with concomitant hypotension and tissue hypoperfusion can adversely influence the length of mechanical ventilation, intensive care unit (ICU) stay, morbidity, and mortality after cardiac surgery as well as OHT. 4, 5 If the vasoplegia is resistant to catecholamines, the mortality rate can be as high as 25%. 2 The exact pathomechanism of perioperative vasoplegia remains poorly understood. 2, 4 However, it is based on an exaggerated inflammatory response determined by the interaction between the immune system priming and CPB surgery, resulting in excessive release of vasoactive mediators and endothelial injury. 2, 4, 6 Patients with advanced stage chronic heart failure are known to have elevated plasma concentrations of pro-inflammatory cytokines and chemokines such as tumor necrosis factor α (TNF-α), interleukin (IL)-6, and IL-8 correlating with the progression of heart failure. 7, 8 CPB surgery is also proven to generate systemic inflammatory response syndrome (SIRS) through complement and cytokine activation and ischemia-reperfusion injury. 9, 10 Additionally, the graft tissue induced response of the host immune system can further aggravate these processes in OHT. 4 The conventional treatment of vasoplegia consists of fluid resuscitation, administration of catecholamine agents, and argininevasopressin or terlipressin. 2 Nevertheless, using vasoconstrictors in high doses, particularly in noradrenaline-refractory cases, increases the risk of peripheral or mesenteric ischemia, leading to a higher rate of postoperative morbidity and mortality. 2, 6 The use of intravenous methylene blue (MB) as an adjuvant might have the potential to control noradrenaline-refractory VS via the inhibition of nitric oxide synthase and nitric oxide in the pathway of activating soluble guanylate cyclase, a key element in the pathomechanism of VS. 2, 6, 11 Despite the significant number of clinical investigations in the field of cardiac and noncardiac surgeries, MB treatment remains controversial in terms of therapeutic effectiveness and in reducing morbidity and mortality. 6, 11 The extracorporeal cytokine hemoadsorption (CytoSorb™) is a novel nonpharmacologic technology, which can effectively remove mid-molecular weight pro-and anti-inflammatory cytokines up to approximately 55 kDa such as TNF-α, IL-1β, IL-6, and IL-10. [12] [13] [14] [15] Recent animal studies have demonstrated its benefit with hemodynamic stability and outcome in a severe sepsis model. 12, 14 Clinical data of patients with septic shock or post-CPB SIRS have also supported the effectiveness of CytoSorb™ treatment, showing hemodynamic improvements and reduction of vasoconstrictors. [16] [17] [18] [19] The aim of this observational study was to explore whether preemptive intraoperative use of CytoSorb™ treatment could influence the severity of perioperative vasoplegia, postoperative inflammatory response, and clinical outcome in patients undergoing OHT.
| MATERIALS AND METHODS

| Patients
This study analyzed prospectively collected clinical data of adult orthotopic heart transplantations performed between January 1, 2015
and December 1, 2016. The study was approved by the Regional and 
| Anesthetic procedure
Anesthesia was provided using sufentanyl bolus 0.25 μg/kg intravenously (IV), propofol bolus 1 mg/kg IV, atracurium bolus 0.3 mg/ kg IV for induction, then a combination of sevoflurane (minimal al- . The CPB prime was composed of 1200 mL Ringer-lactate, 100 mL mannitol, and 60 mL sodium bicarbonate 8.4%. All patients were anesthetized by consultant anesthetists experienced in cardiac anesthesia and OHT.
| Perioperative care
All patients received standardized intra-and postoperative care according to the institutional protocol. Noradrenaline was used as the first line vasopressor, and continuous terlipressin IV infusion The immunosuppression therapy of the heart transplant recipients consisted of mycophenolate mofetil orally 90 minutes before the operation (1.5 g) and daily after the heart transplantation (2.0-3.0 g/ day); methylprednisolone 500 mg IV prior to induction of anesthesia, 500 mg IV 30 minutes after the aortic declamp, 125 mg IV over the first 3 days, and then was continued as oral maintenance treatment;
anti-thymocyte globulin IV infusion (1.5 mg/kg) for the first three postoperative days; tacrolimus orally (0.1-0.2 mg*kg
) from the fifth post-transplant day targeting serum concentration of 10-15 ng/ mL. To exclude early graft rejection, patients were followed up with endomyocardial biopsy weekly during the first month after the heart transplantation. 
| Cytokine adsorption treatment
Selection of heart transplant recipients to receive intraoperative cytokine adsorption (CA) treatment (CytoSorb™, CytoSorbents
Europe GmbH, Berlin, Germany) was based on expert opinion. Endstage heart failure patients complicated by one or more organ dysfunctions prior to heart transplantation, poor functional status with expectation of developing severe VS in the perioperative period had priority for introducing intraoperative CytoSorb™ treatment.
CytoSorb™ was applied for a one-cycle treatment during CPB. The 300-mL CytoSorb™ cartridge was positioned after the oxygenator providing near maximal blood flow through the cartridge via a specified side branch of the CPB circuit. The estimated flow rate through
CytoSorb™ was between 400 mL/min and 500 mL/min depending on the individual flow rate of CPB for all treatments. Taking into account the adsorption spectrum of CytoSorb™ (5-55 kDA fat soluble agents) and its possible effect on drug serum concentration, 23 we considered methylprednisolone (molecular weight < 1 kDA, water soluble) as an immunosuppressive agent, which is not affected and mycophenolate-mofetil (MMF; molecular weight < 1 kDA, slightly water soluble: pKa = 8.5) as an immunosuppressive agent, which is partly, but not significantly affected by CytoSorb™ adsorption.
Supplementary doses of MMF were not administered during the CPB period. 
| Measurement of inflammatory markers
| Outcome parameters
| Statistical analysis
| RESULTS
Ninety-one orthotopic heart transplantations were performed between January 2015 and December 2016 at the Heart and Vascular
Centre of Semmelweis University. Seven patients were excluded from the study, of which five patients reached the exclusion criteria due to death within 72 hours after the heart transplantation and other two patients had retransplantations. The mean age of the study population was 50 ± 10 years and 81% of them were male. Intraoperative CA was used in 24 cases (28.6%). The baseline characteristics and the perioperative clinical data of the study cohort are shown in Table 1 . Table 2 .
| Primary outcome of propensitymatched comparison
Median noradrenaline requirements were similar in the control and CA-treated groups during the heart transplantation procedure (0. , P = .96, 
| Secondary outcome of propensitymatched comparison
There were no differences in postoperative blood loss and number of transfused blood products (ie, packed red blood cell, fresh frozen (Table 3) . Need for re-exploration for bleeding or tamponade was less in the CA-treated patients than in the control group with marginal significance (2 vs 5 cases, P = .06, respectively). Patients in the CA-treated group experienced shorter ventilation times and less acute kidney injury but the differences were not statistically significant. Nevertheless, the frequency of acute or acute-on-chronic renal failure requiring renal replacement therapy was higher in the control group than in CA-treated group (4 vs 2 cases, P = .031, respectively). The incidence of sepsis and early graft rejection did not vary in the two groups. While we did not find any difference in length-of-hospital stay between the two groups, the length-of-ICU stay was shorter in CA-treated group than in control group (10 vs 20 days, respectively) but this difference was not statistically significant. There were no deaths during the first month after transplantation in CA-treated patients compared to two cases in the propensity-matched control group. Details of postoperative complications are summarized in Table 3 . The independent predictors of secondary outcome parameters analyzed in the nonmatched cohort are shown in Table 4 . Additionally, this study did not confirm higher rates of complications including postoperative bleeding, pericardial tamponade, sepsis, and early graft rejection in the CA-treated group.
| DISCUSSION
Patients with end-stage heart failure undergoing OHT are at a remarkably higher risk for developing severe vasoplegia compared to nontransplant cardiac surgery patients. 4, 5, 28 One of the main contributing factors of this difference is the post-CPB inflammatory response.
This is more pronounced in OHT than in conventional cardiac surgery patients due to the pre-existing activation of the immune system by the advanced heart failure and reaction of the host immune system to graft tissue. 4, 29 The rational to introduce the pre-emptive intraoperative CytoSorb™ treatment among OHT recipients was to mitigate and modify this aggravated post-CPB inflammatory response and hopefully prevent development of severe vasoplegia with excessive vaso- patients. 18 However, Bernardi et al found no significant differences in pro-inflammatory cytokine levels and clinical outcome in cardiac surgical patients when they used CytoSorb™ treatment intraoperatively in a blinded, randomized, controlled pilot study. 31 Table 2 ). These data suggest that a shorter period of intraoperative CytoSorb™ treatment (ie, <4 hours) can be clinically effective for controlling postoperative vasoplegia in OHT patients.
We analyzed PCT and CRP as inflammatory markers in the first five postoperative days to quantify post-CPB inflammatory response.
CRP has some limitations in the evaluation of post-CPB inflammatory response, especially in the early postoperative phase. CRP increases after cardiac surgery regardless of the magnitude of SIRS or surgical trauma. 32, 33 PCT is a widely used diagnostic and follow-up marker of infective or noninfective SIRS. 32, [34] [35] [36] Pro-inflammatory cytokines contribute to early PCT induction after surgery resulting in a peak concentration within 24 hours. 32, 34 The peak level of PCT correlates well with the extent of surgical trauma, duration of aortic cross-clamp and CPB, and its dynamics can be a prognostic indicator of complications after cardiac surgery or OHT. 32, 34, 35 In this study, we did not see differences Peng and co-workers confirmed intense cytokine removal, better hemodynamics, and short-term survival after 3 hours of hemoadsorption treatment compared to sham therapy in an animal model of sepsis. 14 Kogelmann et al reported lower mortality than predicted by the APACHE II score associated with early CytoSorb™ treatment in patients with septic shock. 19 Interestingly, these favorable effects of hemoadsorption on outcome were not completely reproducible in the cardiac surgery setting by recent investigations. 18, 31 In our study, clinical outcome showed a positive tendency in the CA-treated patients compared to controls especially in length of MV, ICU stay, frequency of RRT, and mortality although the observed differences in these parameters did reach the level of statistical significance, due, in part, to the small sample size. Furthermore, the complication profile of CA-treated patients was similar but definitely not inferior to controls in terms of postoperative bleeding, sepsis, and early graft rejection.
These positive results can be linked at least in part to significantly less vasopressor demand in the early postoperative period associated with intraoperative CytoSorb™ treatment.
| Limitations
Our investigation does have limitations. This observational study was carried out in a single center which influenced the sample size for the study period. Patient selection for the use of intraoperative cytokine adsorption was based on the arbitrary criteria of clinical experts. This is due to the scarcity of published data in literature related to CytoSorb™ McNemar test. c Early graft rejection was defined by the first surveillance endomyocardial biopsy (EMB) performed on the seventh post-transplant day. EMB grade (International Society for Heart and Lung Transplantation) ≥1A was considered as a positive result for early graft rejection. Based on the first 12 months follow-up data, the frequency of the cardiac allograft vasculopathy was four cases in the CA-treated group vs 0 cases in the control group, P < .0001. Binomial logistic regression, step forward likelihood ratio. Logistic regression did not identify independent predictors of primary graft failure and early graft rejection. OR, odds ratio; CI, confidence interval; MCS, mechanical circulatory support; AKI, acute kidney injury; PRBC, packed red blood cell; OHT, orthotopic heart transplantation.
T A B L E 4 Independent predictors of secondary outcome parameters
treatment, particularly in field of cardiac surgery or OHT due the novelty of this technology. This study completely adhered to the institutional protocol for OHT; therefore, the postoperative inflammatory response was described only by changes in PCT and CRP, and no other pro-inflammatory cytokines for more specific information. These limitations somewhat restrict the interpretation of our results.
| CONCLUSIONS
To the best of our knowledge, this is the first observational study presenting the use of intraoperative CytoSorb™ treatment during OHT. In this study, CytoSorb™ treatment was associated with sig- 
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